A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies

Journal of Drugs in Dermatology

Volumn 13, Issue 7, 2014, Pages 848-853

  Levin, Adriane A ^a,b   Gottlieb, Alice B ^b,c   Au, Shiu Chung ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB; DERMATOLOGICAL AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DERMATOLOGIST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NARROW BAND IMAGING; PSORIASIS; RETROSPECTIVE STUDY; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT FAILURE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNITED STATES; PATHOLOGY; TREATMENT OUTCOME;

CROSS-SECTIONAL STUDIES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84904090102     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Farber EM. Epidemiology: natural history and genetics. In: Roenigk HH Jr, ed. Psoriasis. 3rd ed. New York: Marcel Dekker Inc; 1998:107-157.
2. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16-17. (Pubitemid 32842766)
3. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol. 2002;146(1):118-121. (Pubitemid 34158419)
4. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. (Pubitemid 351239154)
5. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374. (Pubitemid 41443403)
6. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor. Clin Ther. 2010;32(10):1681-1703.
7. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. (Pubitemid 351509656)
8. Au SC, Madani A, Alhaddad M, Alkofide M, Gottlieb AB. Comparison of the efficacy of biologies versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. J Drugs Dermatol. 2013;12(8):861-866.
9. Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm. 2011;68(9):795-806.
10. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol. 2003;120(5):738-741. (Pubitemid 36529071)
11. Naldi L, Svensson A, Zenoni D, et al. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. Br J Dermatol. 2010;162(2):384-389.
12. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091-1096.
13. Brunasso AM, Puntoni M, Massone C. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol. 2012;166(2):447-449.
14. Noiles K, Vender R. Biologic survival. J Drugs Dermatol. 2009;8(4):329-333.
15. Due E, Blomberg M, Skov L, Zachariae C. Discontinuation of methotrexate in psoriasis. Acta Derm Venereol. 2012;92(4):353-354.
16. Puig L. Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J Eur Acad Dermatol Venereol. 2013;27(2):e257-e260.
17. Escande H, Livideanu CB, Steiner A, et al. Incidence and risk factors for treatment failure with infliximab in psoriasis. J Eur Acad Dermatol Venereol. 2013;27(10):1323-1324.
18. Pink AE, Fonia A, Allen MH, Smith CH, Barker JN. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010;162(4):780-785.
19. Ormerod AD. Switching biologies for psoriasis. Br J Dermatol. 2010;163(4):667-669.
20. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65(5):1213-1223.
21. Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72(11):1840-1844.
22. Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab. Br J Dermatol. 2010;163(2):433-434.